| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
| Delaware | 98-1515192 | ||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||
Not Applicable(1) | Not Applicable(1) | ||||
| (Address of principal executive offices) | (Zip Code) | ||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Class A Common Stock, par value $0.0001 per share | CLOV | The NASDAQ Stock Market LLC | ||||||||||||
| Large accelerated filer | x | Accelerated filer | o | |||||||||||
| Non-accelerated filer | o | Smaller reporting company | o | |||||||||||
| Emerging growth company | o | |||||||||||||
| Page | ||||||||
September 30, 2026 | December 31, 2025 | ||||||||||
| Assets | |||||||||||
Current assets: | |||||||||||
| Cash and cash equivalents | $ | 268,067 | $ | 78,301 | |||||||
| Short-term investments | 4,516 | 17,047 | |||||||||
Investment securities, available-for-sale (Amortized cost: 2026: $58,934; 2025: $23,231) | 58,570 | 23,131 | |||||||||
Investment securities, held-to-maturity (Fair value: 2026: $1,565; 2025: $1,779) | 1,582 | 1,777 | |||||||||
| Accrued retrospective premiums | 74,440 | 63,875 | |||||||||
Healthcare receivables | 95,113 | 94,866 | |||||||||
| Prepaid expenses | 16,938 | 18,209 | |||||||||
| Other assets, current | 15,835 | 10,649 | |||||||||
| Total current assets | 535,061 | 307,855 | |||||||||
Investment securities, available-for-sale (Amortized cost: 2026: $170,241; 2025: $186,464) | 167,253 | 187,092 | |||||||||
Investment securities, held-to-maturity (Fair value: 2026: $12,260; 2025: $12,495) | 12,608 | 12,571 | |||||||||
| Property and equipment, net | 7,751 | 6,385 | |||||||||
| Other intangible assets | 2,990 | 2,990 | |||||||||
| Other assets, non-current | 28,017 | 24,118 | |||||||||
| Total assets | $ | 753,680 | $ | 541,011 | |||||||
| Liabilities and Stockholders' Equity | |||||||||||
Current liabilities: | |||||||||||
| Unpaid claims | $ | 269,101 | $ | 153,250 | |||||||
| Accounts payable and accrued expenses | 33,814 | 36,211 | |||||||||
| Accrued salaries and benefits | 36,792 | 16,038 | |||||||||
| Other liabilities, current | 6,192 | 3,324 | |||||||||
| Total current liabilities | 345,899 | 208,823 | |||||||||
| Other liabilities, non-current | 16,909 | 23,484 | |||||||||
| Total liabilities | 362,808 | 232,307 | |||||||||
Commitments and Contingencies (Note 12) | |||||||||||
Stockholders' equity: | |||||||||||
Class A Common Stock, $0.0001 par value; 2,500,000,000 shares authorized at September 30, 2026 and December 31, 2025; 437,698,453 and 426,669,369 issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 43 | 43 | |||||||||
Class B Common Stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2026 and December 31, 2025; 95,713,497 and 92,373,157 issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 9 | 9 | |||||||||
| Additional paid-in capital | 2,716,621 | 2,682,663 | |||||||||
Accumulated other comprehensive (loss) income | (3,352) | 528 | |||||||||
| Accumulated deficit | (2,226,582) | (2,288,352) | |||||||||
Less: Treasury stock, at cost; 35,782,658 and 33,412,273 shares held at September 30, 2026 and December 31, 2025, respectively | (95,867) | (86,187) | |||||||||
| Total stockholders' equity | 390,872 | 308,704 | |||||||||
| Total liabilities and stockholders' equity | $ | 753,680 | $ | 541,011 | |||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
Premiums earned, net (Net of ceded premiums of $87 and $92 for the three months ended September 30, 2026 and 2025 respectively, and $270 and $284 for the nine months ended September 30, 2026 and 2025, respectively) | $ | 748,784 | $ | 479,128 | $ | 2,230,740 | $ | 1,405,860 | |||||||||||||||
| Other income | 10,520 | 17,522 | 20,920 | 30,741 | |||||||||||||||||||
| Total revenues | 759,304 | 496,650 | 2,251,660 | 1,436,601 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Net medical claims incurred | 629,455 | 423,473 | 1,809,268 | 1,154,907 | |||||||||||||||||||
| Salaries and benefits | 55,973 | 48,195 | 167,174 | 168,526 | |||||||||||||||||||
| General and administrative expenses | 66,831 | 48,953 | 211,759 | 148,112 | |||||||||||||||||||
| Depreciation and amortization | 610 | 406 | 1,689 | 1,266 | |||||||||||||||||||
| Total operating expenses | 752,869 | 521,027 | 2,189,890 | 1,472,811 | |||||||||||||||||||
| Income (loss) from operations | 6,435 | (24,377) | 61,770 | (36,210) | |||||||||||||||||||
| Change in fair value of warrants | — | — | — | 19 | |||||||||||||||||||
| Net income (loss) | $ | 6,435 | $ | (24,377) | $ | 61,770 | $ | (36,229) | |||||||||||||||
| Per share data: | |||||||||||||||||||||||
| Basic weighted average number of class A and class B common shares and common share equivalents outstanding | 531,602,371 | 512,743,521 | 527,642,546 | 510,191,111 | |||||||||||||||||||
| Diluted weighted average number of class A and class B common shares and common share equivalents outstanding | 557,476,797 | 512,743,521 | 548,965,149 | 510,191,111 | |||||||||||||||||||
| Basic earnings (loss) per share | $ | 0.01 | $ | (0.05) | $ | 0.12 | $ | (0.07) | |||||||||||||||
| Diluted earnings (loss) per share | $ | 0.01 | $ | (0.05) | $ | 0.11 | $ | (0.07) | |||||||||||||||
| Net unrealized (loss) gain on available-for-sale investments | (1,801) | 294 | (3,880) | 2,055 | |||||||||||||||||||
| Comprehensive income (loss) | $ | 4,634 | $ | (24,083) | $ | 57,890 | $ | (34,174) | |||||||||||||||
| Class A Common Stock | Class B Common Stock | Treasury Stock | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive (loss) income | Total stockholders' equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2025 | 426,669,369 | $ | 43 | 92,373,157 | $ | 9 | 33,412,273 | $ | (86,187) | $ | 2,682,663 | $ | (2,288,352) | $ | 528 | $ | 308,704 | ||||||||||||||||||||||||||||||||||||||||||
| Stock issuance for exercise of stock options, net of early exercise liability | 23,782 | — | — | — | — | — | 30 | — | — | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | 12,451 | — | — | 12,451 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Vested restricted stock units | 4,427,824 | — | 3,342,699 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unrealized holdings loss on investment securities, available for sale | — | — | — | — | — | — | — | — | (1,200) | (1,200) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares withheld for taxes on equity awards | (1,565,397) | — | — | — | 1,565,397 | (7,893) | — | — | — | (7,893) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | 27,334 | — | 27,334 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2026 | 429,555,578 | $ | 43 | 95,715,856 | $ | 9 | 34,977,670 | $ | (94,080) | $ | 2,695,144 | $ | (2,261,018) | $ | (672) | $ | 339,426 | ||||||||||||||||||||||||||||||||||||||||||
| Stock issuance for exercise of stock options, net of early exercise liability | 938,635 | — | — | — | — | — | 1,652 | — | — | 1,652 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | 9,293 | — | — | 9,293 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Vested restricted stock units | 3,472,290 | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unrealized holdings loss on investment securities, available for sale | — | — | — | — | — | — | — | — | (879) | (879) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion from Class B common stock to Class A common stock | 930 | — | (930) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares withheld for taxes on equity awards | (804,988) | — | — | — | 804,988 | (1,787) | — | — | — | (1,787) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock under employee stock purchase plan | 270,199 | — | — | — | — | — | 551 | — | — | 551 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | 28,001 | — | 28,001 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2026 | 433,432,644 | $ | 43 | 95,714,926 | $ | 9 | 35,782,658 | $ | (95,867) | $ | 2,706,640 | $ | (2,233,017) | $ | (1,551) | $ | 376,257 | ||||||||||||||||||||||||||||||||||||||||||
| Stock issuance for exercise of stock options, net of early exercise liability | 1,033,850 | — | — | — | — | — | 1,728 | — | — | 1,728 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | 8,253 | — | — | 8,253 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Vested restricted stock units | 3,230,530 | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unrealized holdings loss on investment securities, available for sale | — | — | — | — | — | — | — | — | (1,801) | (1,801) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion from Class B common stock to Class A common stock | 1,429 | — | (1,429) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | 6,435 | — | 6,435 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2026 | 437,698,453 | $ | 43 | 95,713,497 | $ | 9 | 35,782,658 | $ | (95,867) | $ | 2,716,621 | $ | (2,226,582) | $ | (3,352) | $ | 390,872 | ||||||||||||||||||||||||||||||||||||||||||
| Class A Common Stock | Class B Common Stock | Treasury Stock | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive (loss) income | Total stockholders' equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2024 | 414,493,051 | $ | 41 | 89,032,305 | $ | 9 | 18,752,947 | $ | (30,991) | $ | 2,576,471 | $ | (2,202,803) | $ | (1,584) | $ | 341,143 | ||||||||||||||||||||||||||||||||||||||||||
| Stock issuance for exercise of stock options, net of early exercise liability | 139,709 | — | — | — | — | — | 215 | — | — | 215 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | 26,437 | — | — | 26,437 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Vested restricted stock units | 6,431,417 | 1 | 3,342,698 | — | — | — | — | — | — | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unrealized holdings gain on investment securities, available for sale | — | — | — | — | — | — | — | — | 1,510 | 1,510 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares withheld for taxes on equity awards | (1,833,218) | — | — | — | 1,833,218 | (13,659) | — | — | — | (13,659) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Repurchases of common stock | (5,069,423) | (1) | — | — | 5,069,423 | (18,297) | — | — | — | (18,298) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | (1,274) | — | (1,274) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2025 | 414,161,536 | $ | 41 | 92,375,003 | $ | 9 | 25,655,588 | $ | (62,947) | $ | 2,603,123 | $ | (2,204,077) | $ | (74) | $ | 336,075 | ||||||||||||||||||||||||||||||||||||||||||
| Stock issuance for exercise of stock options, net of early exercise liability | 97,249 | — | — | — | — | — | 148 | — | — | 148 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | 26,195 | — | — | 26,195 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Vested restricted stock units | 6,417,884 | 1 | — | — | — | — | — | — | — | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unrealized holdings gain on investment securities, available for sale | — | — | — | — | — | — | — | — | 251 | 251 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares withheld for taxes on equity awards | (2,476,795) | — | — | — | 2,476,795 | (8,468) | — | — | — | (8,468) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Common Stock under Employee Stock Purchase Plan | 186,901 | — | — | — | — | — | 555 | — | — | 555 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | (10,578) | — | (10,578) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2025 | 418,386,775 | $ | 42 | 92,375,003 | $ | 9 | 28,132,383 | $ | (71,415) | $ | 2,630,021 | $ | (2,214,655) | $ | 177 | $ | 344,179 | ||||||||||||||||||||||||||||||||||||||||||
| Stock issuance for exercise of stock options, net of early exercise liability | 163,180 | — | — | — | — | — | 305 | — | — | 305 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | 26,106 | — | — | 26,106 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Vested restricted stock units | 5,401,427 | 1 | — | — | — | — | — | — | — | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Unrealized holdings gain on investment securities, available for sale | — | — | — | — | — | — | — | — | 294 | 294 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion from Class B Common Stock to Class A Common Stock | 1,846 | — | (1,846) | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares withheld for taxes on equity awards | (2,132,156) | (1) | — | — | 2,132,156 | (5,575) | — | — | — | (5,576) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | (24,377) | — | (24,377) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2025 | 421,821,072 | $ | 42 | 92,373,157 | $ | 9 | 30,264,539 | $ | (76,990) | $ | 2,656,432 | $ | (2,239,032) | $ | 471 | $ | 340,932 | ||||||||||||||||||||||||||||||||||||||||||
| Nine months ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net income (loss) | $ | 61,770 | $ | (36,229) | |||||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization expense | 1,689 | 1,266 | |||||||||
| Stock-based compensation | 29,377 | 78,738 | |||||||||
| Change in fair value of warrants and amortization of warrants | — | 19 | |||||||||
| Accretion, net of amortization | (1,312) | (1,342) | |||||||||
| Change in accrued interest earned | 90 | 726 | |||||||||
| Net realized gains on investment securities | (29) | (625) | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accrued retrospective premiums | (10,565) | (4,317) | |||||||||
| Prepaid expenses | 1,271 | 707 | |||||||||
| Other assets | (9,083) | (10,451) | |||||||||
| Healthcare receivables | (247) | (6,402) | |||||||||
| Unpaid claims | 115,851 | (15,939) | |||||||||
| Accounts payable and accrued expenses | (2,397) | (1,626) | |||||||||
| Accrued salaries and benefits | 20,754 | (1,919) | |||||||||
| Other liabilities | (3,707) | (1,388) | |||||||||
| Net cash provided by operating activities | 203,462 | 1,218 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of short-term investments, available-for-sale, and held-to-maturity securities | (73,053) | (98,991) | |||||||||
| Proceeds from sales of short-term investments and available-for-sale securities | 57,240 | 113,707 | |||||||||
| Proceeds from maturities of short-term investments and available-for-sale securities | 10,271 | 25,801 | |||||||||
| Purchases of property and equipment | (2,434) | (1,446) | |||||||||
| Net cash (used in) provided by investing activities | (7,976) | 39,071 | |||||||||
| Cash flows from financing activities: | |||||||||||
| Issuance of common stock, net of early exercise liability | 3,409 | 668 | |||||||||
| Issuance of common stock under employee stock purchase plan, net of stock issuance costs | 551 | 555 | |||||||||
| Cash paid for shares withheld related to stock-based compensation | (9,680) | (27,702) | |||||||||
| Repurchases of common stock | — | (18,298) | |||||||||
| Net cash used in financing activities | (5,720) | (44,777) | |||||||||
| Net increase (decrease) in cash and cash equivalents | 189,766 | (4,488) | |||||||||
| Cash and cash equivalents, beginning of period | 78,301 | 194,543 | |||||||||
| Cash and cash equivalents, end of period | $ | 268,067 | $ | 190,055 | |||||||
| September 30, 2026 | Amortized cost | Accumulated unrealized gains | Accumulated unrealized losses | Fair value | ||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
Investment securities, held-to-maturity: | ||||||||||||||||||||||||||
U.S. government and government agencies and authorities | $ | 14,190 | $ | — | $ | (365) | $ | 13,825 | ||||||||||||||||||
Investment securities, available-for-sale: | ||||||||||||||||||||||||||
U.S. government and government agencies and authorities | 142,873 | 4 | (2,231) | 140,646 | ||||||||||||||||||||||
| Corporate debt securities | 86,085 | 1 | (1,121) | 84,965 | ||||||||||||||||||||||
| Other | 217 | — | (5) | 212 | ||||||||||||||||||||||
Total held-to-maturity and available-for-sale investment securities | $ | 243,365 | $ | 5 | $ | (3,722) | $ | 239,648 | ||||||||||||||||||
| December 31, 2025 | Amortized cost | Accumulated unrealized gains | Accumulated unrealized losses | Fair value | ||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
Investment securities, held-to-maturity: | ||||||||||||||||||||||||||
U.S. government and government agencies and authorities | $ | 14,348 | $ | 3 | $ | (77) | $ | 14,274 | ||||||||||||||||||
Investment securities, available-for-sale: | ||||||||||||||||||||||||||
U.S. government and government agencies and authorities | 129,217 | 522 | (292) | 129,447 | ||||||||||||||||||||||
Corporate debt securities | 80,197 | 309 | (11) | 80,495 | ||||||||||||||||||||||
| Other | 281 | — | — | 281 | ||||||||||||||||||||||
Total held-to-maturity and available-for-sale investment securities | $ | 224,043 | $ | 834 | $ | (380) | $ | 224,497 | ||||||||||||||||||
| September 30, 2026 | Held-to-maturity | Available-for-sale | ||||||||||||||||||||||||
| Amortized cost | Fair value | Amortized cost | Fair value | |||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||
| Due within one year | $ | 1,582 | $ | 1,565 | $ | 58,934 | $ | 58,570 | ||||||||||||||||||
| Due after one year through five years | 12,497 | 12,180 | 170,241 | 167,253 | ||||||||||||||||||||||
| Due after five years through ten years | — | — | — | — | ||||||||||||||||||||||
| Due after ten years | 111 | 80 | — | — | ||||||||||||||||||||||
| Total | $ | 14,190 | $ | 13,825 | $ | 229,175 | $ | 225,823 | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||
| Cash and cash equivalents | $ | 3,509 | $ | 3,138 | $ | 7,730 | $ | 7,472 | ||||||||||||||||||
| Short-term investments | 28 | — | 163 | — | ||||||||||||||||||||||
| Investment securities | 2,324 | 2,134 | 6,793 | 7,090 | ||||||||||||||||||||||
| Investment income, net | $ | 5,861 | $ | 5,272 | $ | 14,686 | $ | 14,562 | ||||||||||||||||||
| September 30, 2026 | Less than 12 months | Greater than 12 months | Total | |||||||||||||||||||||||||||||||||||
| Fair value | Unrealized loss | Fair value | Unrealized loss | Fair value | Unrealized loss | |||||||||||||||||||||||||||||||||
| (in thousands, except number of positions) | ||||||||||||||||||||||||||||||||||||||
| U.S. government and government agencies and authorities | $ | 144,632 | $ | (2,418) | $ | 5,200 | $ | (178) | $ | 149,832 | $ | (2,596) | ||||||||||||||||||||||||||
| Corporate debt securities | 84,208 | (1,121) | — | — | 84,208 | (1,121) | ||||||||||||||||||||||||||||||||
| Other | 212 | (5) | — | — | 212 | (5) | ||||||||||||||||||||||||||||||||
| Total | $ | 229,052 | $ | (3,544) | $ | 5,200 | $ | (178) | $ | 234,252 | $ | (3,722) | ||||||||||||||||||||||||||
| Number of positions | 212 | 12 | 224 | |||||||||||||||||||||||||||||||||||
| December 31, 2025 | Less than 12 months | Greater than 12 months | Total | |||||||||||||||||||||||||||||||||||
| Fair value | Unrealized loss | Fair value | Unrealized loss | Fair value | Unrealized loss | |||||||||||||||||||||||||||||||||
| (in thousands, except number of positions) | ||||||||||||||||||||||||||||||||||||||
| U.S. government and government agencies and authorities | $ | 16,669 | $ | (38) | $ | 14,626 | $ | (331) | $ | 31,295 | $ | (369) | ||||||||||||||||||||||||||
| Corporate debt securities | 13,733 | (11) | — | — | 13,733 | (11) | ||||||||||||||||||||||||||||||||
| Total | $ | 30,402 | $ | (49) | $ | 14,626 | $ | (331) | $ | 45,028 | $ | (380) | ||||||||||||||||||||||||||
| Number of positions | 24 | 9 | 33 | |||||||||||||||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||
| Proceeds from sales of investment securities | $ | 922 | $ | 34,394 | $ | 57,240 | $ | 113,707 | ||||||||||||||||||
| Proceeds from maturities of investment securities | 2,065 | — | 10,271 | 25,801 | ||||||||||||||||||||||
| Gross realized gains | 1 | 190 | 115 | 635 | ||||||||||||||||||||||
| Gross realized losses | (1) | (2) | (86) | (10) | ||||||||||||||||||||||
| Net realized gains | $ | — | $ | 188 | $ | 29 | $ | 625 | ||||||||||||||||||
| September 30, 2026 | Level 1 | Level 2 | Level 3 | Total Fair Value | ||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||
| U.S. government and government agencies | $ | — | $ | 140,646 | $ | — | $ | 140,646 | ||||||||||||||||||
| Corporate debt securities | — | 84,965 | — | 84,965 | ||||||||||||||||||||||
Private equity investments | — | — | 15,896 | 15,896 | ||||||||||||||||||||||
Other | — | 212 | — | 212 | ||||||||||||||||||||||
| Total assets at fair value | $ | — | $ | 225,823 | $ | 15,896 | $ | 241,719 | ||||||||||||||||||
| December 31, 2025 | Level 1 | Level 2 | Level 3 | Total Fair Value | ||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||
| U.S. government and government agencies | $ | — | $ | 129,447 | $ | — | $ | 129,447 | ||||||||||||||||||
| Corporate debt securities | — | 80,495 | — | 80,495 | ||||||||||||||||||||||
Private equity investments | — | — | 12,226 | 12,226 | ||||||||||||||||||||||
Other | — | 281 | — | 281 | ||||||||||||||||||||||
| Total assets at fair value | $ | — | $ | 210,223 | $ | 12,226 | $ | 222,449 | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||
| Equity investments: | ||||||||||||||||||||||||||
| Balance, beginning of period | $ | 12,226 | $ | — | $ | 12,226 | $ | — | ||||||||||||||||||
| Unrealized gains | 3,670 | 13,424 | 3,670 | 13,424 | ||||||||||||||||||||||
| Transfers into Level 3 | — | 1,826 | — | 1,826 | ||||||||||||||||||||||
| Balance, end of period | $ | 15,896 | $ | 15,250 | $ | 15,896 | $ | 15,250 | ||||||||||||||||||
| Unrealized gains for assets still held at end of period, included in Net income (loss) | $ | 3,670 | $ | 13,424 | $ | 3,670 | $ | 13,424 | ||||||||||||||||||
| Warrants receivable: | ||||||||||||||||||||||||||
| Balance, beginning of period | $ | — | $ | 745 | $ | — | $ | 764 | ||||||||||||||||||
| Realized gains | — | 835 | — | 835 | ||||||||||||||||||||||
| Unrealized losses | — | — | — | (19) | ||||||||||||||||||||||
| Sales | — | (1,579) | — | (1,579) | ||||||||||||||||||||||
| Balance, end of period | $ | — | $ | 1 | $ | — | $ | 1 | ||||||||||||||||||
| Unrealized losses for assets still held at end of period, included in Net income (loss) | $ | — | $ | — | $ | — | $ | (18) | ||||||||||||||||||
| Total Level 3 assets, end of period | $ | 15,896 | $ | 15,251 | $ | 15,896 | $ | 15,251 | ||||||||||||||||||
| Nine Months Ended September 30, | 2026 | 2025 | ||||||||||||
| (in thousands) | ||||||||||||||
Gross and net balance, beginning of period | $ | 153,250 | $ | 156,396 | ||||||||||
| Incurred related to: | ||||||||||||||
| Current year | 1,780,617 | 1,120,914 | ||||||||||||
| Prior years | (16,896) | 9,604 | ||||||||||||
| Total incurred | 1,763,721 | 1,130,518 | ||||||||||||
| Paid related to: | ||||||||||||||
| Current year | 1,522,144 | 991,501 | ||||||||||||
| Prior years | 125,726 | 154,956 | ||||||||||||
| Total paid | 1,647,870 | 1,146,457 | ||||||||||||
Gross and net balance, end of period | $ | 269,101 | $ | 140,457 | ||||||||||
| September 30, 2026 | Shares Authorized Under Plans | Shares Outstanding Under Plans | Shares Remaining Under Plans | |||||||||||||||||
| 2014 Equity Incentive Plan ("2014 Plan") | 54,402,262 | 19,935,678 | N/A | |||||||||||||||||
| 2020 Equity Incentive Plan ("2020 Plan") | 112,256,721 | 32,491,059 | 15,880,558 | |||||||||||||||||
| 2020 Management Incentive Plan ("2020 MIP") | 33,426,983 | — | — | |||||||||||||||||
| 2022 Inducement Award Plan ("Inducement Plan") | 11,000,000 | 866,867 | 1,321,485 | |||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||
| Stock options | $ | — | $ | 42 | $ | 29 | $ | 336 | ||||||||||||||||||
| Restricted Stock Units ("RSUs") | 7,816 | 23,113 | 28,771 | 69,206 | ||||||||||||||||||||||
| Performance Restricted Stock Units ("PRSUs") | 72 | 2,828 | 196 | 8,815 | ||||||||||||||||||||||
| 2020 Employee Stock Purchase Plan ("ESPP") | 134 | 123 | 381 | 381 | ||||||||||||||||||||||
| Total compensation cost recognized for stock-based compensation plans | $ | 8,022 | $ | 26,106 | $ | 29,377 | $ | 78,738 | ||||||||||||||||||
| Number of stock options | Weighted-average exercise price | ||||||||||
Outstanding, January 1, 2026 | 773,859 | $ | 8.88 | ||||||||
| Granted | — | — | |||||||||
| Exercised | — | — | |||||||||
| Forfeited | (187,559) | 8.87 | |||||||||
Outstanding, September 30, 2026 | 586,300 | $ | 8.87 | ||||||||
| Number of stock options | Weighted-average exercise price | ||||||||||
Outstanding, January 1, 2026 | 22,990,399 | $ | 2.75 | ||||||||
| Granted | — | — | |||||||||
| Exercised | (1,996,267) | 1.71 | |||||||||
| Forfeited | (1,058,454) | 2.00 | |||||||||
Outstanding, September 30, 2026 | 19,935,678 | $ | 2.90 | ||||||||
| Number of RSUs | Weighted-average grant date fair value per share | |||||||||||||
Outstanding, January 1, 2026 | 42,953,954 | $ | 3.44 | |||||||||||
| Granted | 9,804,938 | 2.80 | ||||||||||||
| Vested | (14,500,998) | 5.32 | ||||||||||||
| Forfeited | (5,678,613) | 2.01 | ||||||||||||
Outstanding, September 30, 2026 | 32,579,281 | $ | 2.66 | |||||||||||
| Number of PRSUs | Weighted-average grant date fair value per share | |||||||||||||
Non-vested, January 1, 2026 | 27,523,030 | $ | 9.57 | |||||||||||
Granted during 2026 | 192,345 | 1.70 | ||||||||||||
| Vested | — | — | ||||||||||||
| Forfeited | (27,523,030) | 9.57 | ||||||||||||
Non-vested at September 30, 2026 | 192,345 | $ | 1.70 | |||||||||||
| Offering period from May 22, 2026 to November 21, 2026 | ||||||||
| Weighted-average risk-free interest rate | 3.8 | % | ||||||
| Expected term (in years) | 0.50 years | |||||||
| Expected volatility | 52.2 | % | ||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
(in thousands, except for per share and share amounts) | |||||||||||||||||||||||
Numerator: | |||||||||||||||||||||||
| Net income (loss) | $ | 6,435 | $ | (24,377) | $ | 61,770 | $ | (36,229) | |||||||||||||||
Denominator: | |||||||||||||||||||||||
Basic weighted average number of common shares and common share equivalents outstanding | 531,602,371 | 512,743,521 | 527,642,546 | 510,191,111 | |||||||||||||||||||
Dilutive shares: | |||||||||||||||||||||||
RSU | 17,076,158 | N/A | 14,330,623 | N/A | |||||||||||||||||||
PRSU | 143,040 | N/A | 77,957 | N/A | |||||||||||||||||||
Stock Options | 8,655,228 | N/A | 6,914,023 | N/A | |||||||||||||||||||
| Diluted weighted average number of class A and class B common shares and common share equivalents outstanding | 557,476,797 | 512,743,521 | 548,965,149 | 510,191,111 | |||||||||||||||||||
Basic earnings (loss) per share | $ | 0.01 | $ | (0.05) | $ | 0.12 | $ | (0.07) | |||||||||||||||
Diluted earnings (loss) per share | $ | 0.01 | $ | (0.05) | $ | 0.11 | $ | (0.07) | |||||||||||||||
| Three Months Ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Options to purchase common stock | 5,568,270 | 23,828,441 | 5,864,123 | 23,828,441 | |||||||||||||||||||
| RSUs | 865,584 | 37,957,750 | 879,131 | 37,957,750 | |||||||||||||||||||
| PRSUs | — | 28,343,028 | — | 28,343,028 | |||||||||||||||||||
Total potentially dilutive shares excluded from computation of net earnings (loss) per share | 6,433,854 | 90,129,219 | 6,743,254 | 90,129,219 | |||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| Insurance Segment | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
| Premiums earned, net (net of ceded premiums) | $ | 748,784 | $ | 479,128 | $ | 2,230,740 | $ | 1,405,860 | ||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
| Net medical claims incurred | 654,093 | 428,855 | 1,879,515 | 1,190,954 | ||||||||||||||||||||||
| Segment gross profit | $ | 94,691 | $ | 50,273 | $ | 351,225 | $ | 214,906 | ||||||||||||||||||
Reconciliation: | ||||||||||||||||||||||||||
| Elimination of intersegment profits | $ | 24,638 | $ | 5,382 | $ | 70,247 | $ | 36,047 | ||||||||||||||||||
| Other income | 10,520 | 17,522 | 20,920 | 30,741 | ||||||||||||||||||||||
| Salaries and benefits | (55,973) | (48,195) | (167,174) | (168,526) | ||||||||||||||||||||||
| General and administrative expenses | (66,831) | (48,953) | (211,759) | (148,112) | ||||||||||||||||||||||
| Depreciation and amortization | (610) | (406) | (1,689) | (1,266) | ||||||||||||||||||||||
| Change in fair value of warrants | — | — | — | (19) | ||||||||||||||||||||||
Net income (loss) | $ | 6,435 | $ | (24,377) | $ | 61,770 | $ | (36,229) | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||
| Net income (loss) (GAAP): | $ | 6,435 | $ | (24,377) | $ | 61,770 | $ | (36,229) | |||||||||||||||
Adjustments: | |||||||||||||||||||||||
| Salaries and benefits | 55,973 | 48,195 | 167,174 | 168,526 | |||||||||||||||||||
| General and administrative expenses | 66,831 | 48,953 | 211,759 | 148,112 | |||||||||||||||||||
| Depreciation and amortization | 610 | 406 | 1,689 | 1,266 | |||||||||||||||||||
| Change in fair value of warrants | — | — | — | 19 | |||||||||||||||||||
| Consolidated Gross profit (non-GAAP) | $ | 129,849 | $ | 73,177 | $ | 442,392 | $ | 281,694 | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Salaries and benefits | $ | 55,973 | $ | 48,195 | $ | 167,174 | $ | 168,526 | |||||||||||||||
| General and administrative expenses | 66,831 | 48,953 | 211,759 | 148,112 | |||||||||||||||||||
| Total SG&A (GAAP) | 122,804 | 97,148 | 378,933 | 316,638 | |||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Stock-based compensation | (8,022) | (26,106) | (29,377) | (78,738) | |||||||||||||||||||
| Non-recurring legal expenses and settlements | (983) | 24 | (4,387) | (1,234) | |||||||||||||||||||
| Adjusted SG&A (non-GAAP) | $ | 113,799 | $ | 71,066 | $ | 345,169 | $ | 236,666 | |||||||||||||||
| Total revenues (GAAP) | $ | 759,304 | $ | 496,650 | $ | 2,251,660 | $ | 1,436,601 | |||||||||||||||
| Adjusted SG&A (non-GAAP) as a percentage of Total revenues | 15.0 | % | 14.3 | % | 15.3 | % | 16.5 | % | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Net income (loss) (GAAP): | $ | 6,435 | $ | (24,377) | $ | 61,770 | $ | (36,229) | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Depreciation and amortization | 610 | 406 | 1,689 | 1,266 | |||||||||||||||||||
| Change in fair value of warrants | — | — | — | 19 | |||||||||||||||||||
| Stock-based compensation | 8,022 | 26,106 | 29,377 | 78,738 | |||||||||||||||||||
| Non-recurring legal expenses and settlements | 983 | (24) | 4,387 | 1,234 | |||||||||||||||||||
| Adjusted EBITDA (non-GAAP) | $ | 16,050 | $ | 2,111 | $ | 97,223 | $ | 45,028 | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Net income (loss) (GAAP): | $ | 6,435 | $ | (24,377) | $ | 61,770 | $ | (36,229) | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Stock-based compensation | 8,022 | 26,106 | 29,377 | 78,738 | |||||||||||||||||||
| Non-recurring legal expenses and settlements | 983 | (24) | 4,387 | 1,234 | |||||||||||||||||||
| Adjusted Net income (non-GAAP) | $ | 15,440 | $ | 1,705 | $ | 95,534 | $ | 43,743 | |||||||||||||||
| Three Months Ended September 30, | Change Between 2026 and 2025 | ||||||||||||||||||||||
| 2026 | 2025 | ($) | (%) | ||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
Premiums earned, net (Net of ceded premiums of $87 and $92 for the three months ended September 30, 2026 and 2025, respectively) | $ | 748,784 | $ | 479,128 | $ | 269,656 | 56.3 | % | |||||||||||||||
Other income | 10,520 | 17,522 | (7,002) | (40.0) | |||||||||||||||||||
| Total revenues | 759,304 | 496,650 | 262,654 | 52.9 | |||||||||||||||||||
| Operating expenses | |||||||||||||||||||||||
| Net medical claims incurred | 629,455 | 423,473 | 205,982 | 48.6 | |||||||||||||||||||
Salaries and benefits | 55,973 | 48,195 | 7,778 | 16.1 | |||||||||||||||||||
| General and administrative expenses | 66,831 | 48,953 | 17,878 | 36.5 | |||||||||||||||||||
| Depreciation and amortization | 610 | 406 | 204 | 50.2 | |||||||||||||||||||
| Total operating expenses | 752,869 | 521,027 | 231,842 | 44.5 | |||||||||||||||||||
| Income (loss) from operations | 6,435 | (24,377) | 30,812 | * | |||||||||||||||||||
| Net income (loss) | $ | 6,435 | $ | (24,377) | $ | 30,812 | * | ||||||||||||||||
| Nine Months Ended September 30, | Change Between 2026 and 2025 | ||||||||||||||||||||||
| 2026 | 2025 | ($) | (%) | ||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
Premiums earned, net (Net of ceded premiums of $270 and $284 for the nine months ended September 30, 2026 and 2025, respectively) | $ | 2,230,740 | $ | 1,405,860 | $ | 824,880 | 58.7 | % | |||||||||||||||
Other income | 20,920 | 30,741 | (9,821) | (31.9) | |||||||||||||||||||
| Total revenues | 2,251,660 | 1,436,601 | 815,059 | 56.7 | |||||||||||||||||||
| Operating expenses | |||||||||||||||||||||||
| Net medical claims incurred | 1,809,268 | 1,154,907 | 654,361 | 56.7 | |||||||||||||||||||
Salaries and benefits | 167,174 | 168,526 | (1,352) | (0.8) | |||||||||||||||||||
| General and administrative expenses | 211,759 | 148,112 | 63,647 | 43.0 | |||||||||||||||||||
| Depreciation and amortization | 1,689 | 1,266 | 423 | 33.4 | |||||||||||||||||||
| Total operating expenses | 2,189,890 | 1,472,811 | 717,079 | 48.7 | |||||||||||||||||||
| Income (loss) from operations | 61,770 | (36,210) | 97,980 | * | |||||||||||||||||||
Change in fair value of warrants | — | 19 | (19) | * | |||||||||||||||||||
| Net income (loss) | $ | 61,770 | $ | (36,229) | $ | 97,999 | * | ||||||||||||||||
Nine Months Ended September 30, | 2026 | 2025 | ||||||||||||
| (in thousands) | ||||||||||||||
| Cash Flows Data: | ||||||||||||||
| Net cash provided by operating activities | $ | 203,462 | $ | 1,218 | ||||||||||
Net cash (used in) provided by investing activities | (7,976) | 39,071 | ||||||||||||
Net cash used in financing activities | (5,720) | (44,777) | ||||||||||||
Increase (decrease) in cash and cash equivalents | $ | 189,766 | $ | (4,488) | ||||||||||
| Exhibit No. | Description | |||||||
| 31.1* | ||||||||
| 31.2* | ||||||||
| 32.1† | ||||||||
| 32.2† | ||||||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | |||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
| CLOVER HEALTH INVESTMENTS, CORP. | ||||||||
| Date: November 6, 2026 | By: | /s/ Andrew Toy | ||||||
| Andrew Toy | ||||||||
| Chief Executive Officer (Principal Executive Officer) | ||||||||
| Date: November 6, 2026 | By: | /s/ Clay Thornton | ||||||
Clay Thornton | ||||||||
| Chief Financial Officer (Principal Financial Officer) | ||||||||
| Date: November 6, 2026 | By: | /s/ Joe Oldakowski | ||||||
Joe Oldakowski | ||||||||
| Chief Accounting Officer (Principal Accounting Officer) | ||||||||
Date: November 6, 2026 | By: | /s/ Andrew Toy | ||||||
| Andrew Toy | ||||||||
| Chief Executive Officer | ||||||||
Date: November 6, 2026 | By: | /s/ Clay Thornton | ||||||
| Clay Thornton | ||||||||
| Chief Financial Officer | ||||||||
Dated: November 6, 2026 | By: | /s/ Andrew Toy | ||||||
| Andrew Toy | ||||||||
| Chief Executive Officer | ||||||||
Dated: November 6, 2026 | By: | /s/ Clay Thornton | ||||||
| Clay Thornton | ||||||||
| Chief Financial Officer | ||||||||